Market research
FRLN Freeline Therapeutics Holdings Plc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 8.25
- Dividend yield
- Not available
- Beta
- 0.66
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US35655L1070
- Market cap
- 28M
- P/E ratio
- Not available
- Analyst target
- 8.25
- Dividend yield
- Not available
- Beta
- 0.66
About
About Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FRLN discussion.
5 years, 4 months ago
Freeline Therapeutics Holdings plc is currently in a long term downtrend where the price is trading 41.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Freeline Therapeutics Holdings plc gets an overall score of 1/5.